The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis
Open accessAbstract
OBJECTIVE: To assess the efficacy, safety, pharmacokinetics and pharmacodynamics of the anti-interleukin (IL)-1α/β dual variable domain immunoglobulin lutikizumab (ABT-981) in erosive hand osteoarthritis (HOA). METHODS: Patients with ≥1 erosive and ≥3 tender and/or swollen hand joints were randomised to placebo or lutikizumab 200 mg subcutaneously every 2 weeks for 24 weeks. The primary endpoint was change in Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain subdomain score from baseline to 16 weeks. At baseline and week 26, subjects had bilateral hand radiographs and MRI of the hand with the greatest number of baseline tender and/or swollen joints. Continuous endpoints were assessed using analysis of covariance models, with treatment and country as main factors and baseline measurements as covariates. RESULTS: Of 132 randomised subjects, 1 received no study drug and 110 completed the study (placebo, 61/67 (91%); lutikizumab, 49/64 (77%)). AUSCAN pain was not different among subjects treated with lutikizumab versus placebo at week 16 (least squares mean difference, 1.5 (95% CI -1.9 to 5.0)). Other clinical and imaging endpoints were not different between lutikizumab and placebo. Lutikizumab significantly decreased serum high-sensitivity C reactive protein levels, IL-1α and IL-1β levels, and blood neutrophils. Lutikizumab pharmacokinetics were consistent with phase I studies and not affected by antidrug antibodies. Injection site reactions and neutropaenia were more common in the lutikizumab group; discontinuations because of adverse events occurred more frequently with lutikizumab (4/64) versus placebo (1/67). CONCLUSION: Despite adequate blockade of IL-1, lutikizumab did not improve pain or imaging outcomes in erosive HOA compared with placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis
Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J.-P., & Fahmi, H. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.196 · Cited by 2,778
Cited by
Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review
Katz, J. N., Arant, K. R., & Loeser, R. F. (2021) · JAMA · doi:10.1001/jama.2020.22171 · Cited by 2,305
Synovial inflammation in osteoarthritis progression
Sanchez-Lopez, E., Coras, R., Torres, A., Lane, N. E., & Guma, M. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00749-9 · Cited by 1,041
Osteoarthritis year in review 2019: epidemiology and therapy
Kloppenburg, M., & Berenbaum, F. (2020) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2020.01.002 · Cited by 532
Self-citationOverview of MMP-13 as a Promising Target for the Treatment of Osteoarthritis
Hu, Q., & Ecker, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041742 · Cited by 475
Emerging pharmaceutical therapies for osteoarthritis
Latourte, A., Kloppenburg, M., & Richette, P. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00518-6 · Cited by 418
Self-citation
Metadata
- Authors
- Kloppenburg, M., Peterfy, C., Haugen, I. K., Kroon, F., Chen, S., Wang, L., Liu, W., Levy, G., Fleischmann, R. M., Berenbaum, F., van der Heijde, D., Bansal, P., Wittoek, R., Feng, S., Fang, Y., Saltarelli, M., Medema, J. K., & Levesque, M. C.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 78
- Issue
- 3
- Pages
- 413-420
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2904798486
- Cited by
- 174
- References
- 1
- FWCI
- 11.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. https://app.cochat.ai/papers/10.1136/annrheumdis-2018-213336
- The paper
- Kloppenburg, M., Peterfy, C., Haugen, I. K., Kroon, F., Chen, S., Wang, L., Liu, W., Levy, G., Fleischmann, R. M., Berenbaum, F., van der Heijde, D., Bansal, P., Wittoek, R., Feng, S., Fang, Y., Saltarelli, M., Medema, J. K., & Levesque, M. C. (2019). Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2018-213336
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.